Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma

A comprehensive flow cytometry analysis was completed of 27 relapsed/refractory multiple myeloma patients treated with idecabtagene vicleucel to assess the expansion capacity, persistence, and effects on bystander cells of BCMA-targeting CAR T cells. This showed that patients at risk for higher-grade CRS can be identified prior to lymphodepletion. This paper gives practitioners a better understanding of the dynamics and effects of BCMA-targeting CAR T cells, helping predict the response of patients and side effects, which may be prevented or counteracted at an early stage.